The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: Results of a randomized trial

SummaryFifty-eight patients with high-grade astrocytoma were treated by members of the Childrens Cancer Study Group in a prospective randomized trial designed to study the effectiveness of chemotherapy as an adjuvant to standard surgical treatment and radiotherapy. Following surgical therapy, patients were assigned randomly to radiotherapy with or without chemotherapy consisting of chloroethyl-cyclohexyl nitrosourea, vincristine, and prednisone. Treatment with chemotherapy prolonged survival and event-free survival. Five-year event-free survival was 46% for patients in the radiotherapy and chemotherapy group, and 18% for patients in the radiotherapy-alone group. Five-year survival was similarly improved. The differences in outcome due to treatment were statistically significant after correcting for imbalances in important prognostic factors (event-free survival, p = 0.026; survival, p = 0.067). The presence of mitoses or necrosis in the tumor specimen was associated with poorer outcome. Patients whose initial surgery was limited to biopsy, and patients with basal ganglia lesions, also had significantly worse outcome. Chemotherapy administered at the time of recurrence in a small number of patients did not produce any long-term survivors. This study is to our knowledge the only randomized trial to investigate effectiveness of chemotherapy in the treatment of high-grade astrocytoma in children.

[1]  K. Fulling,et al.  Anaplastic astrocytoma of the adult cerebrum. Prognostic value of histologic features , 1985, Cancer.

[2]  M R Paradis,et al.  Tumors of the central nervous system. , 1998, The Veterinary clinics of North America. Equine practice.

[3]  W. Taylor,et al.  Controlled study of CCNU and radiation therapy in malignant astrocytoma. , 1976, Journal of neurosurgery.

[4]  J. Bonnin,et al.  Tumors of the Central Nervous System (I) , 1988 .

[5]  D. Áfra,et al.  Combined radiotherapy and chemotherapy with dibromodulcitol and CCNU in the postoperative treatment of malignant gliomas. , 1983, Journal of neurosurgery.

[6]  V. Levin,et al.  Brain tumor chemotherapy: an evaluation of agents in current use for phase II and III trials. , 1980, Cancer treatment reports.

[7]  L. J. Rubinstein,et al.  Tumors of the central nervous system , 1972 .

[8]  Sheline Ge.  Radiation therapy of primary tumors. , 1975 .

[9]  R. Price,et al.  Brain stem gliomas of children a clinicopathological study , 1983, Cancer.

[10]  V. Oliverio,et al.  Clinical pharmacology of anticancer drugs. , 1977, Seminars in oncology.

[11]  D P Byar,et al.  Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. , 1983, Cancer treatment reports.

[12]  J. Matthias.  Chemotherapy of cancer of the gut. , 1971, The Practitioner.

[13]  D. Bigner,et al.  The biology of malignant gliomas--a comprehensive survey. , 1984, Clinical neuropathology.

[14]  D. Schoenfeld,et al.  Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas . A joint radiation therapy oncology group and eastern cooperative oncology group study , 1983, Cancer.

[15]  S. Green,et al.  Glioblastoma multiforme and anaplastic astrocytoma pathologic criteria and prognostic implications , 1985, Cancer.

[16]  Jensen,et al.  Combined modality treatment of operated astrocytomas grade 3–4. A prospective and randomized study of misonidazole and radiotherapy with two different radiation schedules and subsequent CCNU chemotherapy , 1984 .

[17]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[18]  S. Pocock,et al.  Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. , 1975, Biometrics.

[19]  P. Armitage,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. , 1976, British Journal of Cancer.

[20]  Laurence L. George,et al.  The Statistical Analysis of Failure Time Data , 2003, Technometrics.

[21]  W. Shapiro,et al.  Chemotherapy of primary malignant brain tumors in children , 1975 .

[22]  D. Schoenfeld,et al.  Necrosis as a prognostic criterion in malignant supratentorial, astrocytic gliomas , 1983, Cancer.

[23]  D P Byar,et al.  Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. , 1980, The New England journal of medicine.

[24]  R. Wittes,et al.  Methodologic guidelines for reports of clinical trials. , 1985, Cancer treatment reports.

[25]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[26]  J. Moossy.  Tumors of the Central Nervous System, Atlas of Tumor Pathology, Second Series, Fascicle 6 , 1973, Neurology.

[27]  J. Ware,et al.  Randomized clinical trials. Perspectives on some recent ideas. , 1976, The New England journal of medicine.

[28]  E. Alexander,et al.  Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. , 1978, Journal of neurosurgery.

[29]  N. Bleehen,et al.  An overview of published results from randomized studies of nitrosoureas in primary high grade malignant glioma. , 1987, British Journal of Cancer.